Sensei Biotherapeutics (NASDAQ:FTH) Shares Climb 8.7% – Here’s What Happened

Sensei Biotherapeutics, Inc. (NASDAQ:FTH)’s stock price was up 8.7% on Tuesday. The stock traded as high as $20.70 and last traded at $21.1350. 126,876 shares were traded during mid-day trading, a decline of 48% from the average session volume of 244,265 shares. The stock had previously closed at $19.44.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Lifesci Capital raised shares of Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, October 15th. Needham & Company LLC started coverage on shares of Sensei Biotherapeutics in a research note on Friday, August 21st. They set a “buy” rating and a $56.00 price target on the stock. Raymond James Financial assumed coverage on shares of Sensei Biotherapeutics in a research note on Friday, July 31st. They set an “outperform” rating and a $56.00 price target on the stock. William Blair initiated coverage on shares of Sensei Biotherapeutics in a research report on Friday, October 16th. They set an “outperform” rating for the company. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Sensei Biotherapeutics in a research report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $56.25.

Sensei Biotherapeutics Stock Down 1.1%

The stock has a market capitalization of $531.53 million, a price-to-earnings ratio of -0.15 and a beta of -0.29. The firm has a fifty day moving average of $30.84.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.04) by $2.20. Equities research analysts anticipate that Sensei Biotherapeutics, Inc. will post -11.42 EPS for the current year.

Hedge Funds Weigh In On Sensei Biotherapeutics

Several institutional investors have recently bought and sold shares of the business. Vivo Capital LLC purchased a new stake in shares of Sensei Biotherapeutics during the first quarter valued at about $22,758,000. Alyeska Investment Group L.P. purchased a new position in shares of Sensei Biotherapeutics in the 2nd quarter worth approximately $3,610,000. Stempoint Capital LP purchased a new position in shares of Sensei Biotherapeutics in the 1st quarter worth approximately $4,188,000. Bank of America Corp DE raised its stake in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after acquiring an additional 20,525 shares in the last quarter. 10.50% of the stock is owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.